Supply Issues and Reporting Delays Extend Negotiation Period Beyond 60 Days
Santen Korea's glaucoma treatment, 메이저사이트 Ophthalmic Solution 0.02%, was added to the list of drugs subject to price negotiations in May. However, the process has been delayed as the negotiation results have not yet been reported to the Ministry of Health and Welfare (MOHW), keeping the drug on the negotiation list.
According to a recent investigation by HIT News, Santen Korea has completed price negotiations with the National Health Insurance Corporation and is now awaiting submission of the agenda to the Health Insurance Policy Review Committee. The delay, which has extended beyond the usual 60-day negotiation period, is likely attributed to issues related to supply quantity.
The reason 메이저사이트 remains on the negotiation list, despite the conclusion of negotiations, is believed to be due to the results not yet being reported to the MOHW. A representative from the National Health Insurance Corporation clarified, "Even if negotiations are concluded, the drug remains on the list until the results are reported to the Ministry of Health and Welfare."
메이저사이트 Ophthalmic Solution is designed to lower intraocular pressure in patients with glaucoma or ocular hypertension by selectively inhibiting enzymes that cause the contraction of trabecular meshwork cells, thereby relaxing the trabecular pathway. The drug received product approval from the Ministry of Food and Drug Safety (MFDS) in February of last year.
Clinical studies submitted by the company for approval demonstrated that 메이저사이트 Eye Drops reduced intraocular pressure by up to 5 mmHg in patients with baseline intraocular pressure below 27 mmHg and 30 mmHg, respectively, in comparative trials. Additionally, a clinical trial conducted in the United States confirmed that 메이저사이트 was non-inferior to timolol in reducing intraocular pressure compared to a placebo.
Based on these findings, 메이저사이트 was recognized for its reimbursement appropriateness by the Drug Reimbursement Evaluation Committee in April, leading to its entry into the price negotiation phase. However, the absence of news regarding its reimbursement listing even after the maximum 60-day negotiation period prompted questions.
The launch of 메이저사이트 was delayed due to the postponement of the supply date, which temporarily halted negotiations. Despite this, price negotiations have now been completed, and the drug is awaiting the final approval process by the Health Insurance Policy Review Committee. The potential listing of 메이저사이트 Ophthalmic Solution as a reimbursed treatment could offer more options for glaucoma patients.